首页 | 本学科首页   官方微博 | 高级检索  
     


Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease
Authors:K. Wesnes  C. Edgar  N. Andreasen  P. Annas  H. Basun  L. Lannfelt  H. Zetterberg  K. Blennow  L. Minthon
Affiliation:1. United BioSource Corporation, Goring‐on‐Thames, UK;2. Clinical Trials Consultant, Reading, UK;3. Department of Neurobiology, Caring Sciences and Society, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden;4. Astra Zeneca R&D, S?dert?lje, Sweden;5. Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden;6. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M?lndal, Sweden;7. Clinical Memory Research Unit, Department of Clinical Sciences Malm?, Lund University, Lund, Sweden
Abstract:
Wesnes K, Edgar C, Andreasen N, Annas P, Basun H, Lannfelt L, Zetterberg H, Blennow K, Minthon L. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease.
Acta Neurol Scand: 2010: 122: 270–277.
© 2009 The Authors Journal compilation © 2009 Blackwell Munksgaard. Objectives – Alzheimer’s disease assessment scale‐cognitive subscale (ADAS‐Cog) has become a standard clinical trials outcome for cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized assessment (CDR) system is validated in Alzheimer’s disease (AD). This study was designed to further evaluate validity in relation to ADAS‐Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer’s patients on stable anticholinesterase treatment. Materials and methods – Patients completed cognition assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated. Results – The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months. Conclusions – There are a number of methodological problems with current cognition assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues.
Keywords:cognition  Alzheimer’  s disease  computerized  cognitive drug research system  Alzheimer’  s disease assessment scale‐cognitive subscale  mini mental state examination
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号